key: cord-1041424-qragiabg
authors: Lokhande, Amit S.; Devarajan, Padma V.
title: A Review on Possible Mechanistic Insights of Nitazoxanide for Repurposing in COVID-19
date: 2020-11-20
journal: Eur J Pharmacol
DOI: 10.1016/j.ejphar.2020.173748
sha: 4a4269b8a7be1e6483e393339559aaf380e852ed
doc_id: 1041424
cord_uid: qragiabg

The global pandemic of Coronavirus Disease 2019 (COVID-19) has brought the world to a grinding halt. A major cause of concern is the respiratory distress associated mortality attributed to the cytokine storm. Despite myriad rapidly approved clinical trials with repurposed drugs, and time needed to develop a vaccine, accelerated search for repurposed therapeutics is still ongoing. In this review, we present Nitazoxanide a US-FDA approved antiprotozoal drug, as one such promising candidate. Nitazoxanide which is reported to exert broad-spectrum antiviral activity against various viral infections, revealed good in vitro activity against SARS-CoV-2 in cell culture assays, suggesting potential for repurposing in COVID-19. Furthermore, nitazoxanide displays the potential to boost host innate immune responses and thereby tackle the life-threatening cytokine storm. Possibilities of improving lung, as well as multiple organ damage and providing value addition to COVID-19 patients with comorbidities, are other important facets of the drug. The review juxtaposes the role of nitazoxanide in fighting COVID-19 pathogenesis at multiple levels highlighting the great promise the drug exhibits. The in silico data and in vitro efficacy in cell lines confirms the promise of nitazoxanide. Several approved clinical trials world over further substantiate leveraging nitazoxanide for COVID-19 therapy.

The COVID-19 pandemic has created huge panic and alarm in mankind across the globe. The absence of an assured cure, increase in number of afflicted and the fear of fatality (over half a million deaths worldwide) has created a chaotic ambiance (Sahebnasagh et al., 2020; WHO, 2020) . The concept of repurposing drugs has become the norm for COVID-19 therapy, and clinical trials with repurposed drugs are being approved across the globe at unheard of speeds to find an immediate solution (Guy et al., 2020; Lam et al., 2020) . Direct-acting antivirals, antimalarials, antiparasitics, corticosteroids and biologics singly or in combination are the major candidates being evaluated. The proposed convalescent plasma therapy would find application only in severe emergencies, but is certainly not an alternative for drugs, while vaccines need time to develop (Z. Lam et al., 2020; . The antiviral drugs remdesivir (GS 5734) and favipiravir (Avigan®) have received restricted emergency use approval against COVID-19 (Ethiraj, 2020) , however search for promising therapeutics is still ongoing.

The singular cause for fear is the mortality rate of up to 5%, which is ascribed majorly to the cytokine storm, a hyperimmune host reaction to the virus, which leads to acute respiratory distress syndrome (ARDS) with other major organ failures Khan et al., 2020) .

The cytokine storm attack, known to occur generally in the second week is so sudden and intense, that patients could unexpectedly turn from mild/moderate to severe, needing oxygen support and hospitalisation. If not tackled immediately severe lung damage that follows, often results in death. The approach of combining antiviral efficacy with interventions to curb the cytokine storm, with a single drug or drug combinations appears to be rational, promising and encouraging (Jamilloux et al., 2020; Nile et al., 2020) . In this review we focus on one such promising drug candidate Nitazoxanide (Alinia®) for repurposing in J o u r n a l P r e -p r o o f

SARS-CoV-2 can enter the host cell using two pathways, the endosomal pathway or the fusion based cell surface non-endosomal pathway. As early availability of cell surface proteases is important to facilitate fusion-based entry (Kupferschmidt and Cohen, 2020; Tang et al., 2020) , the endosomal pathway appears to be more favoured.

Fusion between virus and host cell membrane through the non-endosomal pathway results in the viral genetic material being released directly into the host cytosol. This route of entry involves cleavage of viral spike glycoproteins at (S1/S2) interface by host cell surface anchored proteases, transmembrane-protease-serine-2 (TMPRSS2) and furin, exposing fusion S2 peptide available for fusion with host cell membrane (Bestle et al., 2020; Omolo et al., 2020; Ou et al., 2020; Xiu et al., 2020) . Such proteolytic cleavage is dependent on the thiol-disulfide exchange mechanism catalyzed by protein disulfide isomerase (PDI) (Diwaker et al., 2013; Hati and Bhattacharyya, 2020) . PDI also regulates disulphide switch activity in the ectodomains of TMPRSS2 due to presence of cysteine-rich residues (Antalis et al., 2011; Rosewell et al., 2011; Turano et al., 2002) . Nitazoxanide block this oxidoreductase mechanism ( Fig. 2A ) by interacting with cysteine residues of surface-bound PDI through S-nitrosylation (Bekendam et al., 2018; Flaumenhaft et al., 2015; Müller et al., 2008a; Piacentini et al., 2018) . Further, inhibition of furin (Bonacci et al., 2011; Denault et al., 2002; McCarthy et al., 2008) by nitazoxanide can facilitate blocking of other protease signalling pathways, including Wnt/β-catenin (Miner et al., 2019b; Qu et al., 2018) , MAPK/ERK (Shou et al., 2019) , and PI3K/Akt/mTOR (Senkowski et al., 2015; Shou et al., 2020) .

The endosomal route of entry occurs through the angiotensin converting enzyme 2 (ACE2) receptor (Sharifkashani et al., 2020) . The thiol-disulfide redox system governed by PDI assists disulfide bond (-S-S-) exchange between receptor binding domain (S-RBD of S1 fragment) of SARS-CoV-2 spike protein and ACE2 facilitating entry via the endosomal pathway. Reduction of disulphide bonds to thiol (-SH-SH-) impaired such binding (Hati and Bhattacharyya, 2020) . Hence inhibition of the disulphide exchange can inhibit the interaction of S-protein RBD to ACE2, thereby hampering the receptor-mediated endocytosis route of SARS-CoV-2 entry (Fig. 2B ) (Di Santo and Ehrisman, 2013; Diwaker et al., 2013; Müller et al., 2008a; Piacentini et al., 2018) .

A newer entry pathway identified is the Cluster of differentiation 147 (CD147) receptormediated entry which proceeds through the activation of its catalytic domain by integrins and matrix metalloproteinases (MMPs), essential for S-protein binding (Gabison et al., 2005; Han et al., 2008; Liu and Zhu, 2020; Ulrich and Pillat, 2020) . Nitazoxanide through its effect on PDI could inhibit activation of MMPs by blocking the cysteine switch mechanism (Bonacci et al., 2011; McCarthy et al., 2008; Van Wart and Birkedal-Hansen, 1990 ) to prevent such entry. Nitazoxanide can also inhibit other CD-147 mediated signalling pathways, like Wnt/βcatenin signalling (Miner et al., 2019a; Müller et al., 2008a; Qu et al., 2018) , PI3K/Akt/mTOR signalling (Senkowski et al., 2015; Shou et al., 2020) and MAPK/ERK signalling (Shou et al., 2019) .

Receptor mediated entry follows the clathrin mediated endocytic pathway which typically results in early endosome formation and maturation to the late endosome before the contents are released in the cytosol. Such cytosolic release is a crucial step in furthering viral pathogenesis (Bayati et al., 2020; Glebov, 2020) . Nitazoxanide can delay cytosolic release J o u r n a l P r e -p r o o f through its effect on multiple targets (Rossignol, 2014) . Receptor mediated endocytosis dependent on oligomeric clathrin and regulated by two host cell adaptor protein complexes serine−threonine protein kinases, namely AP-2-associated protein kinase 1 (AAK1) and cyclin G-associated kinase (GAK) (Bekerman et al., 2017; Chibber et al., 2020; Stebbing et al., 2020) . Nitazoxanide can inhibit Wnt/β-catenin signalling (El-Kersh et al., 2019; Qu et al., 2018; Shakya et al., 2018b) , which in turn downregulates AAK1 thereby hampering clathrin mediated endocytosis (Agajanian et al., 2019) . Another proposed mechanism is the ability of nitazoxanide to interact with cysteine residues through S-nitrosylation (Andrade and Reed, 2015; Bekendam et al., 2018; Goldman, 2010) , which can hinder the irreversible inhibition of the kinases AAK1 and GAK by interaction with their cysteine residues Cys193 and Cys190 respectively (Sorrell et al., 2016) . These two kinases along with phosphatidylinositol 3-phosphate5-kinase (PIKFYVE) initiates early endosome formation and causes synthesis of phosphatidylinositol-3,5-bisphosphate [PI(3,5)P2] (Phosphoinositides) (Kang et al., 2020; Ou et al., 2020) , which activates two pore segment channel 2 (TPC2), a calcium channel expressed in lysosomal membranes (Filippini et al., 2020; Grimm and Tang, 2020) . TPC2 maintains Ca 2+ homeostasis and the Ca 2+ release from this channel is controlled by nicotinic acid adenine dinucleotide phosphate (NAADP), phosphoinositide and mTOR (X. Petersen et al., 2020) . The endolysosomal lumen serves as an important type of intracellular Ca 2+ store, containing high Ca 2+ concentration of ∼600 μM (Alharbi and Parrington, 2019). In the presence of high endosomal Ca 2+ , the fusion proteins of coronavirus induces better membrane ordering, essential for fusion (Brailoiu and Brailoiu, 2016; Grimm and Tang, 2020) . Nitazoxanide causes depletion of such ATP sensitive intracellular Ca 2+ stores, thus delaying endosome maturation (Ashiru et al., 2014) . Additionally, TPC2 is also regulated by Mg 2+ , the mitogen activated protein kinases (MAPKs), c-jun N-terminal kinase (JNK) and P38 (Alharbi and Parrington, 2019; Jha et al., 2014) , which are inhibited by J o u r n a l P r e -p r o o f nitazoxanide (Senkowski et al., 2015; Shou et al., 2019; Tchouaffi-Nana et al., 2010) , disturbing endosome maturation. The PIKFYVE and TPC2 functions are directly linked to Wnt/β-catenin (Miner et al., 2019a; Qu et al., 2018) and PI3K/Akt/mTOR signalling (Senkowski et al., 2015; Shou et al., 2020) which are via Vacuolar-type H + ATPase (V-ATPase) activates Cathepsin L, which promotes viral-host cell membrane fusion, causing viral genome release into the host cytosol (Collins and Forgac, 2020; Kupferschmidt and Cohen, 2020; Madadlou, 2020; Yang and Shen, 2020) . Nitazoxanide can interact with cysteine residues (Andrade and Reed, 2015; Aqeel et al., 2015; Goldman, 2010) of Cathepsin L, preventing its activation, which leads to inhibition of viral and host cell membrane fusion and consequently the viral genome release (Madadlou, 2020; Nga et al., 2014; Otto and Schirmeister, 1997; Verma et al., 2016) . Furthermore, TIZ which possesses weak acidic pKa~5.8 and lipophilic logP~3.15 (Jurgeit et al., 2012; Miner et al., 2019a) can also induce endosome neutralization analogous to niclosamide (Homolak and Kodvanj, 2020; Jurgeit et al., 2012; Xu et al., 2020) .

Once in the cytosol, the viral genome undergoes translation of open reading frames ORF1a/b through host ribosomes into the large replicase polyprotein 1a (pp1a) and pp1ab, while other ORFs encode structural proteins. These polypeptides (PP1a/PP1ab) are proteolytically cleaved by 3-chymotrypsin like protease (3CLpro or Mpro) and papain-like protease (PLpro) to form several nonstructural proteins (nsp1-16) (Astuti, 2020; Omolo et al., 2020) . The PLpro (nsp3) causes proteolytic processing of nsp1, nsp2, and nsp3 (Klemm et al., 2020) , while 3CLpro (nsp5) processes nsp12, nsp13 and other subunits of the replicase-transcriptase complex (RTC) (Fong, 2020) . Both proteases are key targets for virus multiplication and governing the host directed immune cell response; therefore, they are attractive targets for the antiviral interventions (Shereen et al., 2020) . 3CLpro and PLpro are cysteine rich proteases, J o u r n a l P r e -p r o o f involved in peptide bond hydrolysis (Gil et al., 2020; Pillaiyar et al., 2016) . The schematic representation of binding and interaction of the active metabolite TIZ with these proteases is depicted in Fig. 3 .

The active site of 3CLpro of SARS-CoV-2 contains Cys145 and His41 residues forming a catalytic dyad, (He et al., 2020; Tahir ul Qamar et al., 2020) where cysteine thiol (-SH) functions as a common nucleophile (electron donating group) responsible for proteolytic cleavage (Yang et al., 2003) . SAR studies of pyrazolones and pyrimidines revealed that the presence of aromatic nitro (-NO 2 ) enhances cysteine protease inhibition activity, where the oxygen of the NO 2 forms a H-bond with side chains of Gly143 and Cys145, while the phenyl ring forms hydrophobic interactions (Pillaiyar et al., 2016) . It is therefore proposed that the NO 2 group or the carbonyl carbon of amide bond of TIZ can interact with the catalytic cysteine nucleophile, while phenyl ring could exhibit hydrophobic interactions with the 3CLpro active site (Fig. 3A ) . Recent molecular screening experiments based on linear free energy relationships reported activity of nitazoxanide against 3CLpro with a predicted IC 50 value of 4.36 μM which was comparable with known 3CLpro inhibitors ledipasvir, saquinavir and superior to lopinavir and ritonavir (Fong, 2020) .

The PLpro proteolytic site possess a catalytic triad of Cys112-His273-Asp287 (Báez-Santos et al., 2015; Klemm et al., 2020) where Cys112 acts as thiol nucleophile forming a H-bond with His273 which is paired with Asp287 causing deprotonation of Cys112 (Foster et al., 2003; Stoermer, 2020) . Interaction of electrophilic NO 2 group of nitazoxanide with nucleophilic Cys112 residue at active site through Snitrosylation could reversibly inhibit PLpro function (Foster et al., 2003; Hess et al., 2005; Xian et al., 2000) . The SARS-CoV-2 PLpro has the thumb domain or a blocking loop, containing a critical tyrosine residue Tyr268 (Báez-Santos et al., 2015; Kandeel et al., 2020;  J o u r n a l P r e -p r o o f Klemm et al., 2020) which forms H-bond with the amide nitrogen of PLpro inhibitors, anchoring the inhibitor in the binding site (Báez-Santos et al., 2015; Xian et al., 2000; Yu et al., 2020) . Nitazoxanide exhibits potential as a PLpro inhibitor as the amide nitrogen can form H-bond with Tyr268 ( Fig. 3B ) . Antiprotease activity of nitazoxanide against SARS-CoV-2 is further substantiated by recent in silico molecular modelling study which reported a binding energy score of -110 kJ/mol indicating strong binding and furthermore nitazoxanide shared >70% binding similarity with remdesivir (Abdul Kadhim et al., 2020) .

Synthesis of new genomic viral RNA relies on the multi-subunit replication transcription complex (RTC) which contains multiple enzymes viz. viral RNA-dependent RNA polymerase (RdRp) (nsp12), helicase (nsp13), exonucleases (nsp14) and endonuclease (nsp15) (Omolo et al., 2020; Ulferts et al., 2010) . Such new viral genome synthesis occurs in the protective environment of double membrane vesicles (DMVs) or autophagosomes (Blanchard and Roingeard, 2015; Cottam et al., 2011; Omolo et al., 2020; Wong and Sanyal, 2020) . Nitazoxanide not only exhibits the potential to inhibit all these major enzymes, but can also induce autophagy to disrupt protective environment of autophagosomes (Lam et al., 2012; Senkowski et al., 2015; Shou et al., 2020) . Among the enzymes RdRp plays major role in replication of genomic viral RNA, and RdRp of SARS-CoV-2 shares a 96% sequence identity with SARS-CoV (Aftab et al., 2020; Gao et al., 2020) . Recent molecular docking studies identified nitazoxanide amongst 10 most effective antipolymerase compounds with a docking score -9.76 indicating good binding affinity. Although the score was lower when compared with remdesivir (-14.06), galidesivir (-12.53), ribavirin (-11.88 ) and sofosbuvir (-11.13 ) it was comparable to nafamostat (-9.76), interferon (-9.62 ) and favipiravir (-9 .36) (Aftab et al., 2020) proposing great promise. Helicase (nsp13) promotes the separation of J o u r n a l P r e -p r o o f double stranded RNA to single stranded RNA mediated through nucleotide triphosphate (NTP) hydrolysis-dependent manner (NTPase) (Shu et al., 2020) . Helicase activity can be inhibited by hampering ATP binding or NTPase hydrolysis action, inhibiting nucleic acids interaction and helicase translocation, etc (Briguglio et al., 2011; Habtemariam et al., 2020) .

Reports suggests that, nitazoxanide inhibits oxidative phosphorylation leading to decreased ATP levels and causes viral protein misfolding, thereby inhibiting helicase ATP dependent action (Hemphill et al., 2006; Piacentini et al., 2018) . The nsp14, exoribonuclease (ExoN) is a proofreading 3′-5′ exoribonuclease which help overcome errors caused in RNA replication, and helps modulate dsRNA levels and innate immune sensing (da Silva et al., 2020) . ExoN activity depends on divalent metal ions Mg 2+ and low concentration of Zn 2+ , while Ca 2+

inactivates ExoN (Chen et al., 2007; Minskaia et al., 2006) . Loss of ExoN proofreading has been found to enhance the antiviral effect of remdesivir (Agostini et al., 2018; Shannon et al., 2020) . As nitazoxanide affects Mg 2+ (Tchouaffi-Nana et al., 2010) and enhances intracellular Ca 2+ release (Ashiru et al., 2014), its action on ExoN is proposed. A recent molecular docking study revealed the partial binding affinity of nitazoxanide to NendoU with glide score of -5.5, which is comparable with known antiviral drug remdesivir score -5.6 (Joshi and Poduri, 2020) proposing action on the endoribonuclease (nsp15). Nsp15 encodes a specific protein called NendoU, which acts by cleaving single and double-stranded RNA catalyzed by Mn 2+ dependent manner (Senanayake, 2020) , and helps the virus evade the host innate immune reaction (Kim et al., 2020) . However, mutations in the nsps are an important cause of drug resistance, a major therapeutic challenge. Notably, nitazoxanide which is reportedly found to be less prone to such resistance, could thus serve as a safe, and effective antiviral intervention (Tilmanis et al., 2020) . In vitro drug screening assay against coronavirus identified that nitazoxanide can inhibit viral N-protein expression, enhanced green fluorescent protein (EGFP) reporter gene expression and viral production (Cao et al., 2015) .

Artificial intelligence study exhibited better interaction score of nitazoxanide with the coatomer protein complex 2 subunit (COPB2) gene, involved in replication of SARS-CoV-2, confirming potential of nitazoxanide for repurposing against COVID-19 (Avchaciov et al., 2020) .

Protective environment of DMVs or autophagosomes concealing viral RNA is formed by the attachment of RTC with membrane derived from ER (Blanchard and Roingeard, 2015; Knoops et al., 2008) , enabling it to escape the dsRNA-triggered host antiviral response (Astuti, 2020; Kumar et al., 2020; Margaritopoulos et al., 2017) . SARS-CoV-2 escapes autophagy by inhibiting the activation of AMP-protein activated kinase (AMPK), and by promoting the mammalian activation target of rapamycin complex 1 (mTORC1) (Shojaei et al., 2020; Wong and Sanyal, 2020) . Nitazoxanide promotes autophagy leading to degradation of DMVs contents by activating AMPK and inhibiting mTORC1, thereby adversely affecting virus genome synthesis ( Fig. 4) (Cottam et al., 2011; Senkowski et al., 2015; Shou et al., 2020 Shou et al., , 2019 . The ability of nitazoxanide also increases intracellular Ca 2+ levels, induces ER stress and thereby induces protective unfolded protein response (UPR) activation, leading to autophagy (Ashiru et al., 2014; Ehrisman, 2014, 2013) .

Out of many kinases, Beclin-1 acts as a master regulator of autophagy, which promotes the phagophore sequestration and enables the fusion of autophagosomes with lysosomes (Gassen et al., 2019; Lundin et al., 2014) . While the conversion of Light chain LC3-I to LC3-II induces autophagosome maturation, the cargo receptor p62/sequestome1 (p62/SQSTM1) induces autophagic flux (Rubinsztein et al., 2012; Vakifahmetoglu-Norberg et al., 2015) . TIZ 

Nitazoxanide therefore exhibits the ability to inhibit various targets of viral genome synthesis.

The newly synthesized mRNAs are rapidly translated to the ER for producing and processing structurally associated proteins and budded in association with golgi bodies in the form of compartments called ER-golgi compartment. This compartment then encloses viral genome and promotes virion assembly. Finally, virions assembly are enclosed within smooth vesicles causing exocytosis of virion particles ready to infect neighbouring cells and other tissues Zumla et al., 2016) . Ca 2+ induces major post-translational changes in the recently synthesized viral proteins within ER lumen (Stutzmann and Mattson, 2011) . 

COVID-19 causes a complicated clash between host antiviral innate immunity and continuous upsurge of inflammatory markers, the latter being responsible for a fatal condition called "Cytokine storm" (Coperchini et al., 2020; Samudrala et al., 2020) . High systemic levels of interleukins, interferons, interferon inducible protein, tumour necrosis factor, growth factors, colony-stimulating factors, macrophage inflammatory protein, monocyte chemoattractant protein, chemokines are a hallmark of the SARS-CoV-2 cytokine storm (Costela-Ruiz et al., 2020; Henderson et al., 2020; Pearce et al., 2020; Samudrala et al., 2020) . Nitazoxanide causes activation of innate immune responses and induction of hostdirected antiviral mechanisms, thereby exhibiting great promise against the SARS-CoV-2 cytokine storm (Fig. 5) (Mahmoud et al., 2020; Padmanabhan, 2020; Padmanabhan and Padmanabhan, 2020) .

The viral RNA expresses pathogen-associated molecular patterns (PAMPs) Interferon-β (TRIF), mitochondrial antiviral-signalling protein (MAVS) and stimulator of interferon genes protein (STING) to activate downstream signalling effectors, i.e. MyD88, the transcription factor nuclear factor-κB (NF-κB) and interferon regulatory factor 3/7 (IRF3/7) (Frieman and Baric, 2008; Guo et al., 2020; Lei and Hilgenfeld, 2017) . SARS-CoV 2 prevents IRF3/7 signalling, suppresses Type I Interferon (IFN-I) release and inhibits JAK/STAT signalling (Gordon et al., 2020; Jamilloux et al., 2020; Zumla et al., 2016) . While NF-ĸB activation leads to the secretion of pro-inflammatory markers (TNF-α, IL-1β, IL-6, IFN-γ, IL-17), IRF3/7 activation induces secretion of IFN-I, which suppresses viral replication and spread, helps cell recovery and boosts adaptive immunity (Costela-Ruiz et al., 2020) . The IFN secretion triggers the JAK1/TYK2-STAT1/2 pathway, inducing production of numerous IFN stimulated genes (ISGs) in the nucleus (Jamilloux et al., 2020) .

Nitazoxanide treatment thus results in broad amplification of the host immune responses, including an increase in RLR activation, enhanced MAVS and IRF3 activities, and induction of the antiviral phosphatase GADD34 (Jasenosky et al., 2019) . Also Nitazoxanide mediates J o u r n a l P r e -p r o o f phosphorylation of protein kinase RNA (PKR) and eukaryotic initiation factor 2α (eIF2α) leading to the enhanced IFN-I secretion (Ashiru et al., 2014; Haas et al., 2020) . Moreover, the viral genome proteins ORF3a, ORF8b and E activate NLR signalling and JNK signalling, which then triggers caspase-1, NF-kB signalling, stimulate pro-inflammatory cytokines and induces cell apoptosis (Freeman and Swartz, 2020; Shah, 2020) . Nitazoxanide inhibited the production of pro-inflammatory cytokines TNF-α, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 in peripheral blood mononuclear cells (Rossignol, 2016) , exhibited downregulation of IL-6/JAK2/STAT3 pathway and significantly modulated the p53/caspases-dependent signalling pathways affecting apoptosis (Tantawy et al., 2020) . TIZ treatment reduced inflammation in macrophage cell lines by suppressing NF-κB, MAPK and PI3K/Akt/mTOR pathway (Shou et al., 2019) , whereas in case of LPS induced inflammatory microglia, TIZ treatment decreased the release of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, chemokines like CCL-2 and CCL-3, intrinsic nitric oxide synthase (iNOS) and cyclooxygenase2 (COX2) expression (X. W. Trabattoni et al., 2016) . Thus in the case of COVID-19 patients, nitazoxanide could serve as a potential candidate, curbing the inflammation and activating host innate immune responses crucial for addressing SARS-CoV-2 pathogenesis (Martins-Filho et al., 2020) .

In COVID-19 patients, lung damage is attributed to shedding of SARS-CoV-2 entry receptor ACE2 in the extracellular milieu mediated by A disintegrin and metallopeptidase domain 17 (ADAM17) (Costela-Ruiz et al., 2020; Krossa et al., 2018; Palau et al., 2020; Vitiello and Ferrara, 2020) . ADAM17 activation, impaired IFN-I response and persistent lymphopenia (lymphocyte count < 1.5 X 10 9 /L) increases accumulation of lymphocytes in the lungs and other lymphoid organs with circulating higher levels of inflammatory cytokines (Venet et al., 2009; Yuki et al., 2020) . The resulting inflammation, vascular leakage and enormous lung J o u r n a l P r e -p r o o f epithelial and endothelial cells damage, causes the acute respiratory distress syndrome (ARDS) (Costela-Ruiz et al., 2020; Hoffmann et al., 2020; Jamilloux et al., 2020; Venet et al., 2009; Vitiello and Ferrara, 2020; Zhang et al., 2020) . This is further aggravated by downregulation of innate immunity and T-cell exhaustion, which makes COVID-19 patients immunocompetent (Diao et al., 2020; Samudrala et al., 2020; Tay et al., 2020) . In one clinical case report, nitazoxanide treatment provided better relief to immunocompetent host infected with lung crypotosporidiosis, who presented with fever, cough, breathlessness, followed by diarrhoea, and had lung consolidation conditions similar to COVID-19 (Kumar et al., 2016) .

In inflammatory lung conditions, there is downregulation of UPR and upregulation of PDI.

In allergic airway disease model, ablation of PDI in lung epithelial cells, reduced apoptotic, Ehrisman, 2014, 2013) . The UPR consists of three pathways regulating the ER stress, which decreases protein load by promoting folding or otherwise induces extended UPR to cause apoptosis. Each UPR pathway involves a particular signalling molecule, including inositol-requiring protein-1 (IRE1), protein kinase RNA (PKR)-like ER kinase (PERK) and activating transcription factor-6 (ATF6) (Ron and Walter, 2007; Sureda et al., 2020) . The IRE1 causes mRNA splicing and activation of tumour necrosis factor associated factor 2 (TRAF2) triggering downstream inflammatory and apoptotic signalling J o u r n a l P r e -p r o o f (Rajapaksa et al., 2015) . CoV induces prolonged IRE1 and activates TRAF2 Lim et al., 2016) . In contrast, nitazoxanide induces glutathione Stransferase P1 (GSTP1) which inhibits TRAF2 (Müller et al., 2008b) . CoV induces ATF-6 to release ER chaperone proteins like PDI , whereas nitazoxanide being a PDI inhibitor, plays a crucial role in maintaining protective UPR response (Di Ehrisman, 2014, 2013) . PERK which causes phosphorylation of the eIF2α and induces Activating Transcription Factor 4 (ATF4), protecting the cell against oxidative damage (Sureda et al., 2020) , is inhibited by CoV, while nitazoxanide upregulates the ATF4 mechanism (Ashiru et al., 2014). Nitazoxanide mediated UPR signalling via PERK activation can exhibit antiprotease and antioxidant activity by stimulating nuclear factor erythroid 2related factor 2 (Nrf2) through NADPH quinone oxidoreductase1, a critical response against respiratory viral infection, including coronaviruses (Antalis et al., 2011; Curry Jr and Rosewell, 2008; Rosewell et al., 2011; Victor et al., 2020) . Furthermore, the calcium binding proteins, translationally controlled tumour protein (TCTP) and binding immunoglobulin protein (BiP) are activated within cytosol and ER respectively, during nitazoxanide therapy to balance Ca 2+ concentration, thus inhibiting apoptosis (Ashiru et al., 2014; Di Santo and Ehrisman, 2014) . Another important aspect is the potent bronchodilation activity of nitazoxanide comparable to β-agonist isoproterenol, attributed to its role as antagonist to the Ca 2+ -Activated-Cl¯ channel transmembrane member 16A (TMEM16A). This proposes a new mechanism of bronchodilation useful in treatment of severe lung inflammatory diseases, asthma and COPD. Nitazoxanide therefore exhibits great promise in alleviating lung damage (Miner et al., 2019a) .

In COVID-19 patients, the elevated levels of C-reactive protein, erythrocyte sedimentation rate, serum amyloid A and ferritin, respiratory distress, vascular leakage and coagulation, J o u r n a l P r e -p r o o f neuronal damage result in fatalities often associated with multiple organ failures (Chibber et al., 2020; Kermali et al., 2020; Nile et al., 2020; Samudrala et al., 2020; Zeng et al., 2020) .

Interestingly, inhibition of PDI by nitazoxanide can play an important role in preventing multiple organ damage reported in COVID-19 patients. In case of cardiovascular diseases, PDI supports plaque formation and causes coagulation (Li et al., 2016) , whereas in case of diabetes it hampers insulin release and prevents lowering of blood glucose (Mohan et al., 2019; Shergalis and Neamati, 2016) . Similarly, in cancer patients, cell migration, invasion and metastasis is mediated through PDI activity (Lee, 2017; Xu et al., 2014) . Moreover, in case of brain disorders, nitazoxanide inhibited neurodegeneration (Perri et al., 2016; Uehara et al., 2006; Verkhratsky and Petersen, 2002) . Further, in the case of liver diseases activation of prolonged UPR signalling and PDI plays a crucial role in disease progression (Maiers and Malhi, 2019; Mohan et al., 2019) . Renal fibrosis also exhibits high secretory level of PDI (ERP57) causing kidney damage (Dihazi et al., 2013 ). Yet another mechanism by which nitazoxanide exhibits multiple organ protection is via phosphodiesterases (PDEs) inhibition (WO2018173069A1) (Deshpande et al., 2018) . PDEs causes phosphodiesteric bond cleavage in cyclic nucleotides, cAMP and cGMP, leading towards fibrosis, memory loss, pulmonary hypertension, vasoconstriction, renal dysfunction and various other multiple organ damage (Mondaini, 2020; Santing et al., 2001; Sharma et al., 2013; Thomas et al., 2001) . Thus inhibiting PDI, PDEs and simultaneously activating protective UPR signalling could be critical in effective therapy of patients with comorbidities like cardiovascular disease, cancer, diabetes, kidney, liver and brain disorders (Di Santo and Ehrisman, 2013; Müller et al., 2008a) .

Nitazoxanide has demonstrated superior efficacy against coronavirus replication in cell culture assays at low micromolar concentrations (Rossignol, 2014) . Recent reports on 

Nitazoxanide is a hydrophobic drug with low aqueous solubility (~7.5 μg/ml) and high permeability, which dictates its dose-dependent therapeutic efficacy. Nitazoxanide exhibits oral bioavailability of about 30%, which can rise upto 50% with food (Rossignol, 2014; Stachulski et al., 2018) . Its low bioavailability and poorly discovered lung concentrations, are major challenges that need to be addressed (Anderson and Curran, 2007; Padmanabhan, 2020; Padmanabhan and Padmanabhan, 2020; Rajoli et al., 2020) . In adults, nitazoxanide dose of 500 mg twice-daily achieved peak concentration of 10 µg/ml, at approximately 2-4 h for TIZ, while 1 g twice daily dose achieved the peak concentration of 24 µg/ml (Fox and Saravolatz, 2005; Jr, 2004) . Moreover, nitazoxanide controlled-release tablets 300mg twicedaily dose exhibited peak plasma concentrations of 4.6 μg/ml which is well above its in vitro antiviral concentration (Haffizulla et al., 2014; Rossignol, 2014) . The estimated IC 50 and IC 90 of nitazoxanide against SARS-CoV-2 are 0.68 μg/ml and 1.84 μg/ml respectively, which can be readily achieved using frequent dosing . The physiologically-based pharmacokinetic (PBPK) modelling reported the optimal doses of nitazoxanide as 1200 mg four times, 1600 mg three times, 2900 mg twice daily in the fasted state and 700 mg four times, 900 mg three times and 1400 mg twice daily when given with food, to provide its plasma and lung concentrations well above its reported in vitro 90% effective concentration (EC 90 ) against SARS-CoV-2 (4.64 μM or 1.43 μg/ml) (Rajoli et al., 2020) . Furthermore, one study utilized the ratio of C max /EC 90 based on approved human dose of nitazoxanide, which exhibited the ratio value above 1 indicating plasma C max J o u r n a l P r e -p r o o f concentrations exceeded those necessary to inhibit 90% of SARS-CoV-2 replication (Arshad et al., 2020). Interestingly, nitazoxanide is well tolerated up to 4 g daily dose and its LD 50 is higher than 10,000 mg/kg, indicating high safety. Nitazoxanide high dose of 1 g two times daily administered in AIDS patients suffering from diarrhoea, devoid of any severe side effects (Fox and Saravolatz, 2005; Jr, 2004) . Thus nitazoxanide is effective and safe therapeutic intervention and its estimated generic pricing is $1.41 for a 14-day COVID-19 treatment at 500 mg twice daily dose (Mahmoud et al., 2020; Martins-Filho et al., 2020; Pepperrell et al., 2020) , which makes therapy inexpensive.

The clinical pathology of COVID-19 is characterized as mild, moderate, severe and critical (Siddiqi and Mehra, 2020) . The life-threatening challenges emerge in severe and critical phases attributed to the cytokine storm (Chibber et al., 2020; Samudrala et al., 2020; Soy et al., 2020; . While, favipiravir, remdesivir, umifenovir and hydroxychloroquine may act at early and mild to moderate phases, nitazoxanide holds promise to act even in the severe phase due to the potential to curb the cytokine storm (Krishna et al., 2020; Nyarko et al., 2020; Omolo et al., 2020; Sanders et al., 2020) .

Dexamethasone also found effective against cytokine storm (Horby et al., 2020; Robinson, 2020) . Furthermore, the possibility of nitazoxanide in therapy of patients with comorbidities is certainly exciting. Fig. 6 depicts the various stages of COVID-19 and compares nitazoxanide with some of the promising emergency use approved drug candidates for COVID-19.

Number of clinical trials registered using nitazoxanide as the only drug or in combination with other antivirals further substantiates the hypothesis on the high promise of nitazoxanide J o u r n a l P r e -p r o o f (Mahmoud et al., 2020; Martins-Filho et al., 2020) . A total of 19 new clinical trials for COVID-19, have been registered in the USA, Egypt, Mexico, Argentina, Nigeria and Brazil in the past five months, between April to August 2020 (https://clinicaltrials.gov/) (Nitazoxanide clinical trials, 2020). Of these registered trials ten trials are nitazoxanide alone while the other nine are combinations of nitazoxanide with antivirals (Table 1) . Notably, in the majority of registered clinical trials, the nitazoxanide dose is increased to 500 mg or 600 mg twice a day and more. Moreover, nitazoxanide has also been proposed in combination with other potential drugs such as hydroxychloroquine, ivermectin and ribavirin. These trials indeed emphasise the promise of the drug for COVID-19. A recent study identified 73 combinations of potential 32 drugs against SARS-CoV-2 using in silico modelling and further validated them through in vitro studies. The study reported high synergy of nitazoxanide with three antivirals remdesivir, amodiaquine and umifenovir. The study also reports that the combination of remdesivir and hydroxychloroquine demonstrated strong antagonism (Bobrowski et al., 2020) . The combination use of nitazoxanide with macrolide antibiotic azithromycin (Kelleni, 2020) and antimalarial drug hydroxychloroquine has been proposed (Padmanabhan, 2020) .

Although nitazoxanide demonstrated efficacy in clinical studies against Influenza, HBV, HCV, rotavirus, rhinovirus/ enterovirus infections, it was never approved/marketed for these indications, due to poor significance over the placebo group. Although the clinical study against uncomplicated influenza demonstrated efficacy, the results were not convincing given only 1-2 log reduction in viral titer and minor difference in time for discharge between placebo (116.7 h) and test arms (nitazoxanide 300mg twice daily 95.5 h and nitazoxanide 300mg once daily 109.1 h) (Haffizulla et al., 2014) . We contend that the dose was probably low. The differences would have probably been evident with further increase in dose to J o u r n a l P r e -p r o o f 500mg twice a day or through the design of a bioenhanced formulation. The Mexico trial involving Nitazoxanide against Severe acute respiratory illness (SARI), found discouraging, with highlighted reasons for the same. It said, negative results might be associated with low plasma drug levels, which attributed to low dose and poor bioavailability. They also highlighted other limitations of their study, which included the heterogeneous patient population, a variety of factors affecting decisions related to the primary endpoint (hospital discharge), and limited sample size. Also, the maximum dose selected was 300mg twice daily for five days (Gamiño-Arroyo et al., 2019) .

The phase 3 global study data on uncomplicated influenza involved a higher dose of nitazoxanide 600mg twice daily (1.2 gm/day) alone or in combination with oseltamavir 75mg twice daily (NCT01610245). The results are however not available yet. This study substantiates our premise on the need for a higher dose. Nitazoxanide requires further translational development and de-risking studies to conclude its effective use in clinical situation to provide benefit to COVID-19 victims.

Nitazoxanide an FDA approved antiprotozoal, safe, inexpensive and well-tolerated old drug, proposes great potential for repurposing against COVID-19. In this review we highlight proposed mechanism of nitazoxanide against numerous targets involved in SARS-CoV-2 pathogenesis affecting viral entry and multiplication. The potential of nitazoxanide to inhibit the inflammatory cytokine storm while simultaneously stimulating innate immune responses presents great promise to prevent ARDS. The ability to protect the lung, avert associated multiple organ damage, and the beneficial effects in SARS-CoV-2 patients with comorbidities proposes nitazoxanide as a promising candidate for repurposing in COVID-19.

Nitazoxanide presents exciting possibilities for repurposing in COVID-19. The drug is approved as an antiprotozoal and for localized action in the gastro-intestinal tract (GIT).

Hence considering strategies to enhance bioavailability could be an important approach to enhance efficacy at possibly lower doses (Omolo et al., 2020) . Furthermore, directing the drug in high concentration to the target site following oral administration could be achieved by lymphatic targeting of oral particulate carriers (Bachhav et al., 2018 (Bachhav et al., , 2017 . With the myriad targets the drug exhibits potential to attack in the pathogenesis of COVID-19, let us hope it is the panacea the world seeks to overcome the fatality and the fear of COVID-19. 

Tizoxanide (TIZ) activates Beclin1, PI3KCIII and AMPK which leads to activation of ULK1 inducing autophagosome formation. TIZ also increases cytosolic Ca 2+ concentration through IP 3 R by depleting ER Ca 2+ store inducing ER stress and activating protective UPR signalling.

TIZ causes conversion of LC3I to LC3II, degradation of and inhibits PI3KCI/Akt/mTOR signalling, all together promoting autophagy. AMPK, AMP-protein activated kinase; ER, Endoplasmic reticulum; IP 3 R, Inositol trisphosphate receptor; LC3, Light chain 3; p62/SQSTM1, cargo receptor p62/sequestome1; PI3KCI, Phosphatidylinositol-3-kinase class I; PI3KCIII, Phosphatidylinositol-3-kinase class III; PI3KCI/Akt/mTOR, phosphatidylinositol-3-kinase/ protein kinase B/ mammalian target of rapamycin; ULK1/2, Unc-51-like kinase-1/2; UPR, Unfolded protein response.

SARS-CoV-2 entry via ACE2 is hampered by TIZ which regulates renin-angiotensin system by blocking angiotensin II binding to its receptors (AT1R and AT2R), to provide protective responses. ADAM-17 mediated ACE2 shedding is prevented by TIZ due to PDI inhibition, Table Caption   Table 1 Clinical studies registered on Nitazoxanide/ Nitazoxanide combinations against COVID-19 (Updated 28 August 2020) J o u r n a l P r e -p r o o f 

Preprocessing of the Candidate Antiviral Drugs against COVID-19 in Models of SARS cov2 Targets

Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach

WNT Activates the AAK1 Kinase to Promote Clathrin-Mediated Endocytosis of LRP6 and Establish a Negative Feedback Loop

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Protein disulfide isomerase regulation by nitric oxide maintains vascular quiescence and controls thrombus formation

Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects

TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells

Virus-induced double-membrane vesicles

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro

Electrophilic fatty acids regulate matrix metalloproteinase activity and expression

Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum

Regulation and function of V-ATPases in physiology and disease

The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

Coronavirus nsp6 proteins generate autophagosomes from the endoplasmic reticulum via an omegasome intermediate

A Potential Role of MMP2 and MMP9 in Regulation of Hepsin and Protein Disulfide Isomerase from Granulosa Cells

A Potential Role of MMP2 and MMP9 in Regulation of Hepsin and Protein Disulfide Isomerase from Granulosa Cells

Role of Nonstructural Proteins in the Pathogenesis of SARS-CoV-2

Ectodomain shedding of furin: kinetics and role of the cysteine-rich region

Therapeutic agent for phosphodiesterase inhibition and its related disorders

A functional perspective of nitazoxanide as a potential anticancer drug

Research Perspective: Potential Role of Nitazoxanide in Ovarian Cancer Treatment. Old Drug, New Purpose?

Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)

Secretion of ERP57 is important for extracellular matrix accumulation and progression of renal fibrosis, and is an early sign of disease onset

Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?

Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease

Screening potential anti-virals for the main protease of the Coronaviridae family including SARS-CoV-2

S-nitrosylation in health and disease

Nitazoxanide: a new thiazolide antiparasitic agent

Targeting the NLRP3 inflammasome in severe COVID-19

Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation. Microbiol

Coronavirus-induced ER stress response and its involvement in regulation of coronavirus-host interactions

Human Coronavirus: Host-Pathogen Interaction

Coronavirus infection, ER stress, apoptosis and innate immunity

EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair

Mexico Emerging Infectious Diseases Clinical Research Network (LaRed), 2019. Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection

Successfully Treated Norovirus-and Sapovirus-Associated Diarrhea in Three Renal Transplant Patients. Case Rep

COVID-19: Drug targets and potential treatments

Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing

Maximizing bactericidal activity with combinations of bioreduced drugs

A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing

Could an endo-lysosomal ion channel be the Achilles heel of SARS-CoV2?

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status

Rapid repurposing of drugs for COVID-19

Highthroughput analysis identifying drugs that reduce oxidative and ER stress in human coronary artery endothelial cells

Should we try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebocontrolled, phase 2b/3 trial

Current approaches to the treatment of gastrointestinal infections: focus on nitazoxanide

MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer

Impact of Thiol-Disulfide Balance on the Binding of Covid-19 Spike Protein with Angiotensin-Converting Enzyme 2 Receptor

Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS

CoV-2 drugs: Insights from structures of protease and inhibitors

Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections

On the alert for cytokine storm: Immunopathology in COVID-19

Protein Snitrosylation: purview and parameters

Protein disulfide isomerase-endoplasmic reticulum resident protein 57 regulates allergen-induced airways inflammation, fibrosis, and hyperresponsiveness

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Widely available lysosome targeting agents should be considered as potential therapy for COVID-19

Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report

Cytokine and anti-cytokine interventions

The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits Ebola virus

Convergent regulation of the lysosomal two-pore channel-2 by Mg2+, NAADP, PI(3,5)P2 and multiple protein kinases

Targeting Two-Pore Channels: Current Progress and Future Challenges

Drug treatment of coronavirus disease 2019 (COVID-19) in China

Virtual screening enabled selection of antiviral agents against Covid-19 disease targeting coronavirus endoribonuclease NendoU: Plausible mechanistic interventions in the treatment of new virus strain

Nitazoxanide: a new broad spectrum antiparasitic agent

Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects

Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease

Inhibition of PIKfyve kinase prevents infection by EBOV and SARS-CoV-2

Nitazoxanide/Azithromycin Combination for COVID-19: A Suggested New Protocol for COVID-19 Early Management

The role of biomarkers in diagnosis of COVID-19-A systematic review

Coronavirus diseases 2019: Current biological situation and potential therapeutic perspective

Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2

Mechanism and inhibition of SARS-CoV-2 PLpro

SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum

Antiviral activity of substituted salicylanilides--a review

Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection

Redundancy of protein disulfide isomerases in the catalysis of the inactivating disulfide switch in A Disintegrin and Metalloprotease 17

Pulmonary cryptosporidiosis in an immunocompetent host treated successfully with nitazoxanide

Action of nitroheterocyclic drugs against Clostridium difficile

Extracellular matrix metalloproteinase inducer enhances host resistance against pseudomonas aeruginosa infection through MAPK signaling pathway

Human Coronaviruses: A Review of Virus-Host Interactions

Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19

Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients

Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus

Food proteins are a potential resource for mining cathepsin L inhibitory drugs to combat SARS-CoV-2

Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?

Endoplasmic reticulum stress in metabolic liver diseases and hepatic fibrosis, in: Seminars in Liver Disease

Toll-like receptors and autophagy in interstitial lung diseases

Potential role for nitazoxanide in treating SARS-CoV-2 infection

Nitric oxide regulation of MMP-9 activation and its relationship to modifications of the cysteine switch

Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways

Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways

Discovery of an RNA virus 3′→5′ exoribonuclease that is critically involved in coronavirus RNA synthesis

Endoplasmic reticulum stress: A master regulator of metabolic syndrome

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?

Neospora caninum: Functional inhibition of protein disulfide isomerase by the broad-spectrum antiparasitic drug nitazoxanide and other thiazolides

Thiazolides inhibit growth and induce glutathione-S-transferase Pi (GSTP1)-dependent cell death in human colon cancer cells

Studies of Inhibitory Mechanisms of Propeptide-Like Cysteine Protease Inhibitors

COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons

A Comparison Analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the Treatment of Corona Virus Disease 2019 (COVID-19)-A Review

Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus

Cysteine Proteases and Their Inhibitors

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with Nitazoxanide and Hydroxychloroquine

Nitazoxanide-a potential ally in the treatment of COVID-19

ADAM17 inhibition may exert a protective effect on COVID-19

The cytokine storm of COVID-19: a spotlight on prevention and protection

Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19

Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency

The unfolded protein response and the role of protein disulfide isomerase in neurodegeneration

Endocytic uptake of SARS-CoV-2: the critical roles of pH, Ca 2+ , and NAADP. Function 1, zqaa003

Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57

An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy

Small molecule promotes βcatenin citrullination and inhibits Wnt signaling in cancer

ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

Everything you need to know about the COVID-19 therapy trials

Signal integration in the endoplasmic reticulum unfolded protein response

Identification of Hepsin and Protein Disulfide Isomerase A3 as Targets of Gelatinolytic Action in Rat Ovarian Granulosa Cells During the Periovulatory Period

Effect of Nitazoxanide in Diarrhea and Enteritis Caused by Cryptosporidium Species

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Nitazoxanide: a first-in-class broad-spectrum antiviral agent

Thiazolides: a new class of antiviral drugs

Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Posttranslational Level

Autophagy modulation as a potential therapeutic target for diverse diseases

The prophylaxis and treatment potential of supplements for COVID-19

Virology, pathogenesis, diagnosis and in-line treatment of COVID-19

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

Bronchodilatory and anti-inflammatory properties of inhaled selective phosphodiesterase inhibitors in a guinea pig model of allergic asthma

Overcoming nonstructural protein 15-nidoviral uridylate-specific endoribonuclease (nsp15/NendoU) activity of SARS-CoV-2. Future Drug Discovery FDD 42

Three-dimensional cell culture-based screening identifies the anthelmintic drug nitazoxanide as a candidate for treatment of colorectal cancer

Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19

Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent

Update on nitazoxanide: a multifunctional chemotherapeutic agent

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites

Angiotensinconverting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting

Phosphodiesterases: Regulators of cyclic nucleotide signals and novel molecular target for movement disorders

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

Protein Disulfide Isomerase

Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway

Tizoxanide inhibits inflammation in LPS-Activated

macrophages via the suppression of NF-κB and MAPK activation

Tizoxanide induces autophagy by inhibiting PI3K/Akt/mTOR pathway in RAW264. 7 macrophage cells

SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Comparative analysis of the activation of unfolded protein response by spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus HKU1

Family-wide Structural Analysis of Human Numb-Associated Protein Kinases

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

Second-generation nitazoxanide J o u r n a l P r e -p r o o f derivatives: thiazolides are effective inhibitors of the influenza A virus

COVID-19: combining antiviral and anti-inflammatory treatments

Homology Models of the Papain-Like Protease PLpro from Coronavirus

Protein disulfide isomerase and host-pathogen interaction

Endoplasmic Reticulum Ca2+ Handling in Excitable Cells in Health and Disease

Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?

Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants

Coronavirus membrane fusion mechanism offers as a potential target for antiviral development

Synthetic antiprotozoal thiazolide drug

/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study

The trinity of COVID-19: immunity, inflammation and intervention

Nitazoxanide Inhibits Biofilm Formation by Staphylococcus epidermidis by Blocking Accumulation on Surfaces

Chronic type IV phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine

Hosttargeted Nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir

Thiazolides elicit anti-viral innate immunity and reduce HIV replication

Proteins of the PDI family: unpredicted non-ER locations and functions

S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration

Expression and functions of SARS coronavirus replicative proteins

CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Pharmacologic agents targeting autophagy

The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family

Pharmacological modulation of nucleic acid sensors -therapeutic potential and persisting obstacles

Lymphocytes in the Development of Lung Inflammation: A Role for Regulatory CD4+ T Cells in Indirect Pulmonary Lung Injury

The endoplasmic reticulum as an integrating signalling organelle: from neuronal signalling to neuronal death

Cysteine Proteases: Modes of Activation and Future Prospects as Pharmacological Targets

Pharmacological activation of Nrf2 promotes wound healing

Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

WHO, 2020. WHO Coronavirus Disease (COVID-19) Dashboard

Manipulation of autophagy by (+) RNA viruses

Inhibition of papain by Snitrosothiols. Formation of mixed disulfides

Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities

Broad spectrum antiviral agent niclosamide and its therapeutic potential

Protein disulfide isomerase: a promising target for cancer therapy

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19

Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking

COVID-19 pathophysiology: A review

Association of inflammatory markers with the severity of COVID-19: A meta-analysis

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Coronaviruses-drug discovery and therapeutic options